Paper36230815
Histological Subtypes Drive Distinct Prognostic Immune Signatures in Classical Hodgkin Lymphoma.
Lamaison C and 10 others. Cancers (Basel), 2022. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Histological Subtypes Drive Distinct Prognostic Immune Signatures in Classical Hodgkin Lymphoma. Papers, record 36230815. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36230815
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Histological Subtypes Drive Distinct Prognostic Immune Signatures in Classical Hodgkin Lymphoma.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References43
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32641598 | Clinicopathological significance of CD79a expression in classic Hodgkin lymphoma. | J Clin Exp Hematop | 2020 | https://conductscience.org/library/papers/32641598 | PubMed |
| 2 | 27733358 | Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin lymphoma. | Blood | 2017 | https://conductscience.org/library/papers/27733358 | PubMed |
| 3 | 25486870 | The IL-15 cytokine system provides growth and survival signals in Hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells. | Leukemia | 2015 | https://conductscience.org/library/papers/25486870 | PubMed |
| 4 | 22667341 | Macrophage, mast cell and T lymphocyte infiltrations are independent predictive biomarkers of primary refractoriness or early relapse in classical Hodgkin lymphoma. | Leuk Lymphoma | 2013 | https://conductscience.org/library/papers/22667341 | PubMed |
| 5 | 20959606 | CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. | Blood | 2011 | https://conductscience.org/library/papers/20959606 | PubMed |
| 6 | 26980727 | The 2016 revision of the World Health Organization classification of lymphoid neoplasms. | Blood | 2016 | https://conductscience.org/library/papers/26980727 | PubMed |
| 7 | 2356855 | Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin's disease. | Am J Pathol | 1990 | https://conductscience.org/library/papers/2356855 | PubMed |
| 8 | 20220182 | Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20220182 | PubMed |
| 9 | 25482239 | PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. | N Engl J Med | 2015 | https://conductscience.org/library/papers/25482239 | PubMed |
| 10 | 27737878 | Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. | Cancer Immunol Res | 2016 | https://conductscience.org/library/papers/27737878 | PubMed |
| 11 | 26406983 | Expression of Interleukin-1 and Interleukin-1 Receptors Type 1 and Type 2 in Hodgkin Lymphoma. | PLoS One | 2015 | https://conductscience.org/library/papers/26406983 | PubMed |
| 12 | 11154228 | Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. | Blood | 2001 | https://conductscience.org/library/papers/11154228 | PubMed |
| 13 | 19096012 | Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. | Blood | 2009 | https://conductscience.org/library/papers/19096012 | PubMed |
| 14 | 18924115 | Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. | Hematol Oncol | 2009 | https://conductscience.org/library/papers/18924115 | PubMed |
| 15 | 23045593 | Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23045593 | PubMed |
| 16 | 33567641 | Genomic Landscape of Hodgkin Lymphoma. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33567641 | PubMed |
| 17 | 11159538 | Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. | Blood | 2001 | https://conductscience.org/library/papers/11159538 | PubMed |
| 18 | 24766492 | CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment. | Leuk Lymphoma | 2015 | https://conductscience.org/library/papers/24766492 | PubMed |
| 19 | 33936943 | Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience. | Leuk Res Rep | 2021 | https://conductscience.org/library/papers/33936943 | PubMed |
| 20 | 32352505 | Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/32352505 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42654466 | Quantity Does Not Matter: Number, Ratio, or Grouping of Hodgkin/Reed-Sternberg Cells Does Not Affect Prognosis in Patients with Classic Hodgkin Lymphoma. | Medicina (Kaunas) | 2026 | https://conductscience.org/library/papers/42654466 | PubMed |
| 39669843 | A Decade of Prevalence and Clinicopathological Insights Into Classical Hodgkin Lymphoma: A Study From an Indonesian Tertiary Hospital. | Cureus | 2024 | https://conductscience.org/library/papers/39669843 | PubMed |
| 39517391 | Unusual Signal of Lymphadenopathy in Children with Nodular Sclerosing Hodgkin Lymphoma. | Healthcare (Basel) | 2024 | https://conductscience.org/library/papers/39517391 | PubMed |
| 37345063 | Hodgkin Lymphoma-The Spectrum from Diagnostics to Molecular Science, Movement and Current Treatment Approaches. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37345063 | PubMed |
Genes52
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36230815
GET https://conductscience.org/api/papers/v1/36230815/references?page=2